EPS for Aduro BioTech, Inc. (ADRO) Expected At $-0.30

April 20, 2018 - By Marguerite Chambers

Analysts expect Aduro BioTech, Inc. (NASDAQ:ADRO) to report $-0.30 EPS on May, 1.They anticipate $0.02 EPS change or 6.25 % from last quarter’s $-0.32 EPS. After having $-0.35 EPS previously, Aduro BioTech, Inc.’s analysts see -14.29 % EPS growth. It closed at $7.1 lastly. It is down 11.85% since April 20, 2017 and is downtrending. It has underperformed by 23.40% the S&P500.

Aduro BioTech, Inc. (NASDAQ:ADRO) Ratings Coverage

Among 4 analysts covering Aduro BioTech (NASDAQ:ADRO), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Aduro BioTech had 6 analyst reports since October 30, 2017 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Wednesday, November 1 with “Buy”. As per Wednesday, December 13, the company rating was maintained by Oppenheimer. The firm has “Buy” rating given on Monday, October 30 by Oppenheimer. The stock has “Buy” rating by H.C. Wainwright on Wednesday, December 13. The firm has “Underperform” rating given on Friday, March 2 by Bank of America.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. The company has market cap of $575.15 million. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. It currently has negative earnings. The firm is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract.

Aduro BioTech, Inc. (NASDAQ:ADRO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.